Sector News

Heptares, Sosei shuffle leadership as CSO Marshall departs

January 22, 2018
Life sciences

Fiona Marshall, Ph.D., is set to leave Sosei. Marshall has served as CSO of the company since it bought Heptares but is now departing to take on a senior role at another business.

Sosei responded to the resignation of Marshall—who will leave at the end of next month—by giving Malcolm Weir, Ph.D., responsibility for its R&D activities. Weir, like Marshall, joined Sosei through the takeover of British GPCR specialist Heptares. Marshall and Weir co-founded Heptares and, as CSO and CEO, respectively, led it to a $400 million (£287 million) takeover by Sosei.

Since then, Heptares and its team have been integral to Sosei’s plans. Both Marshall and Weir hold EVP positions, with the former taking the CSO title and the latter serving as chief R&D officer. With Marshall departing, Sosei’s R&D activities will continue under Weir’s leadership.

Weir will get support from the newly promoted Tim Tasker, M.D. Tasker, who joined Heptares a year before the 2015 Sosei takeover, is now the Japanese company’s CMO and part of its executive team. The promotion of a doctor with decades of experience running trials at Evotec and GlaxoSmithKline comes at a time when Sosei is preparing to ramp up its clinical development activities.

“[Tasker’s] expertise is crucial to supporting our partnered programs and more importantly to drive our proprietary programs, of which we plan to advance at least six candidates into clinical studies over the next two years, including HTL0018318, our selective muscarinic M1 agonist, which we expect to start a phase 2 trial in patients with dementia with Lewy bodies in Japan during this year,” Sosei CEO Peter Bains said in a statement.

Shares in Sosei traded down 6% following news of Marshall’s departure.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.